Maryam Alsadat Mousavi

[ 1 ] - After introduction of advanced therapeutic medicinal products (ATMPs) in Ischemic Stroke; novel therapeutic modalities from financial perspective

Stroke, is accounting for more than 34% of total healthcare spending globally. Ischemic stroke (IS) accounts for 62.4% of incident stroke cases. IS-related direct medical expenditures place a considerable burden on healthcare system. The burden is more prominent in developing countries where limitations in insurance coverage is a big concern. It would be less challenging in developed countries,...